WO2013137433A1 - 3剤を組み合わせた新規な抗腫瘍剤 - Google Patents
3剤を組み合わせた新規な抗腫瘍剤 Download PDFInfo
- Publication number
- WO2013137433A1 WO2013137433A1 PCT/JP2013/057403 JP2013057403W WO2013137433A1 WO 2013137433 A1 WO2013137433 A1 WO 2013137433A1 JP 2013057403 W JP2013057403 W JP 2013057403W WO 2013137433 A1 WO2013137433 A1 WO 2013137433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- paclitaxel
- gimeracil
- tegafur
- combination
- oteracil potassium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a combination drug containing tegafur, gimeracil and oteracil potassium, oxaliplatin (hereinafter also referred to as “1-OHP”), and a novel antitumor agent containing paclitaxel.
- 5-fluorouracil hereinafter “5-FU”
- cisplatin irinotecan
- paclitaxel docetaxel
- tegafur uracil combination drug trade name: UFT (registered trademark)
- UFT registered trademark
- TS-1 registered trademark
- TS Anti-tumor agents such as -1 have been clinically applied as single agents or in combination.
- Non-patent Document 1 a combination chemotherapy of TS-1 and cisplatin is expected as a combination chemotherapy showing a stronger life-prolonging effect.
- TS-1 and l-OHP combined therapy is a useful treatment that has a high therapeutic effect on advanced and recurrent colorectal cancer, etc., but to contribute to long-term survival for gastric cancer patients, A therapeutic method that exhibits a stronger antitumor effect and has fewer side effects is expected.
- paclitaxel is known as an antitumor agent similar to the taxane system that inhibits the division of tumor cells by binding to microtubules for stabilization and inhibiting depolymerization.
- TS-1 paclitaxel
- paclitaxel is known as an antitumor agent similar to the taxane system that inhibits the division of tumor cells by binding to microtubules for stabilization and inhibiting depolymerization.
- TS-1 and paclitaxel Non-patent Document 3
- An object of the present invention is to provide a novel antitumor agent and an antitumor treatment method exhibiting a remarkable antitumor effect, particularly a tumor growth delaying effect.
- TS-1 / l-OHP a treatment method using TS-1 and l-OHP in combination
- TS-1 / l-OHP a treatment method using TS-1 and l-OHP in combination
- the present invention includes the following inventions 1) to 33).
- An antitumor agent comprising a combination of tegafur, gimeracil and oteracil potassium-containing combination agent, oxaliplatin and paclitaxel.
- the antitumor according to any one of 1) to 2) above which is a preparation comprising a combination preparation containing tegafur, gimeracil and oteracil potassium, a preparation containing oxaliplatin, and a preparation containing paclitaxel. Agent.
- a combination drug containing tegafur, gimeracil and oteracil potassium is 60 to 120 mg / m 2 in terms of tegafur as a daily dose
- oxaliplatin is 80 to 150 mg / m 2 in a daily dose
- paclitaxel is 1 6.
- the antitumor agent according to any one of 1) to 5) above, which contains 50 to 500 mg / m 2 as a daily dose.
- a kit comprising a combination drug containing tegafur, gimeracil and oteracil potassium, a preparation containing oxaliplatin, and a preparation containing paclitaxel.
- the route of administration in which the combination drug containing tegafur, gimeracil and oteracil potassium is selected from the group consisting of intravenous, intramuscular and subcutaneous, respectively, the formulation containing oxaliplatin and the formulation containing paclitaxel, depending on the route of oral administration The kit according to any one of 8) to 9) above, wherein the kit is administered by
- a combination preparation containing tegafur, gimeracil and oteracil potassium, a preparation containing oxaliplatin, and a preparation containing paclitaxel are administered simultaneously or at intervals, 8) to 10 above
- a combination containing tegafur, gimeracil and oteracil potassium 60-120 mg / m2 in terms of tegafur as a daily dose, 80-150 mg / m2 in a daily dose of oxaliplatin, and daily dose of paclitaxel The kit according to any one of the above 8) to 11), wherein the kit contains 50 to 500 mg / m 2 respectively.
- a method for treating a tumor comprising administering a combination drug containing tegafur, gimeracil and oteracil potassium, oxaliplatin, and paclitaxel.
- the formulation containing oxaliplatin and the formulation containing paclitaxel selected from the group consisting of intravenous, intramuscular and subcutaneous The method according to 16) above, which is administered.
- a combination drug containing tegafur, gimeracil and oteracil potassium is 60 to 120 mg / m 2 in terms of tegafur as a daily dose, 80 to 150 mg / m 2 in daily dose of oxaliplatin, 1 19.
- kits including a combination drug containing tegafur, gimeracil and oteracil potassium, wherein the combination drug is combined with oxaliplatin and paclitaxel to treat a tumor patient
- a kit characterized in that it contains documentation, labels or instructions for use.
- Paclitaxel for use in tumor therapy in combination with a combination drug containing tegafur, gimeracil and oteracil potassium and oxaliplatin.
- Paclitaxel for treating a tumor patient by administering a combination drug containing tegafur, gimeracil and oteracil potassium and oxaliplatin simultaneously or at intervals.
- Paclitaxel according to any one of the above 26) to 27), wherein the preparation form is a nanoparticle preparation in which paclitaxel is encapsulated with albumin.
- a kit comprising a label or instructions for use.
- kits according to 29) above, wherein the preparation form of paclitaxel is a nanoparticle preparation in which paclitaxel is encapsulated with albumin.
- paclitaxel for the manufacture of a medicament for treating a tumor in combination with a combination drug containing tegafur, gimeracil and oteracil potassium and paclitaxel.
- the present invention relates to the following inventions.
- the antitumor agent according to 1) above which is a preparation form comprising (1) three components of tegafur, chimeracil and oteracil potassium, and (2) a preparation containing oxaliplatin and paclitaxel as active ingredients.
- the ratio of the active ingredient is 1-5 mol of gimeracil, 0.1-5 mol of oteracil potassium, 0.1-5 mol of oxaliplatin, and 0.01-100 mol of paclitaxel with respect to 1 mol of tegafur.
- the antitumor agent is a kit comprising (1) a combination drug of tegafur, gimeracil and oteracil potassium, (2) a drug containing oxaliplatin and (3) a drug containing paclitaxel.
- An antitumor composition comprising (a) a therapeutically effective amount of tegafur, an effective amount of gimeracil for enhancing antitumor effects, and an effective amount of oteracil potassium for side effect suppression, (b) treatment An antitumor composition containing an effective amount of oxaliplatin, and (c) a combination of pharmaceutical compositions for tumor treatment in a mammal comprising an antitumor composition containing a therapeutically effective amount of paclitaxel kit.
- the antitumor agent comprising the combination of tegafur, gimeracil and oteracil potassium of the present invention, 1-OHP, and paclitaxel has an antitumor effect significantly higher than that of the conventional antitumor agent, for example, It reduces tumor volume and stagnant tumor growth. Therefore, patients can obtain a longer survival time by using the antitumor agent of the present invention.
- the antitumor agent of the present invention using tegafur, gimeracil and oteracil potassium-containing compounding agents, l-OHP and paclitaxel in combination, when used alone or in combination of two agents
- the antitumor effect is evaluated as a tumor reduction effect, a tumor growth delay effect, or the like.
- tegafur, gimeracil and oteracil potassium are mixed in an arbitrary ratio, and a pharmaceutically acceptable carrier as described later is appropriately added. Preparations prepared in this way.
- Tegafur is a known compound represented by 5-fluoro-1- (2-tetrahydrofuryl) -2,4- (1H, 3H) -pyrimidinedione.
- Tegafur is a drug that is activated in vivo to release 5-FU, which is the main body of antitumor activity.
- Tegafur can be produced according to a known method, for example, the method described in JP-B-49-10510.
- Gimeracil is a known compound represented by 2,4-dihydroxy-5-chloropyridine. Gimeracil itself has no antitumor activity, but suppresses 5-FU being metabolized and inactivated in vivo, and can enhance the antitumor effect. .
- Oxyl potassium is a known compound represented by monopotassium 1,2,3,4-tetrahydro-2,4-dioxo-1,3,5-triazine-6-carboxylate. Oteracil potassium itself has no antitumor activity, but it is mainly distributed in the gastrointestinal tract and inhibits gastrointestinal disorders by suppressing the activation of 5-FU at that site.
- the mixing ratio of tegafur, gimeracil and oteracil potassium is not particularly limited as long as each mixing purpose is achieved.
- it may be in the same range as a known compounding agent described in Japanese Patent No. 2614164, and gimeracil is about 0.1 to 5 mol, preferably 0.2 to 1.5 mol, per 1 mol of tegafur.
- the amount of oteracil potassium may be about 0.1 to 5 mol, preferably about 0.2 to 2 mol.
- Oxaliplatin (1-OHP) of the present invention is a known compound represented by cis-oxalate (1R, 2R-diaminocyclohexane) platinum (II).
- l-OHP has the action of causing tumor dysfunction by causing DNA dysfunction and DNA strand breakage by binding to tumor cell DNA.
- l-OHP can be produced according to a known method, for example, the method described in JP-B-60-41077.
- the mixing ratio of 1-OHP in the antitumor agent of the present invention is not particularly limited as long as the antitumor effect is enhanced.
- 1-OHP is about 0.1 to 5.0 mol, preferably about 0.2 to 3.0 mol, particularly preferably 0.4 to 2.0 mol. It should be about.
- the “paclitaxel” of the present invention is a known compound that exerts an antitumor effect by inhibiting the depolymerization of microtubules of the cytoskeleton and arresting the cell cycle at the G2 / M phase to inhibit cell division.
- Paclitaxel is known to have an antitumor effect on ovarian cancer, non-small cell lung cancer, breast cancer, stomach cancer, endometrial cancer and the like.
- the paclitaxel of the present invention includes paclitaxel derivatives and drug delivery system (DDS) preparations for the purpose of alleviating the side effects of paclitaxel.
- DDS drug delivery system
- a nanoparticle preparation of paclitaxel encapsulated in albumin-bound suspension of paclitaxel for injection (trade name “Abraxane”)
- a polymer micelle body in which paclitaxel is encapsulated in a block copolymer of polyethylene glycol and polyaspartic acid NK105
- NK105 polymer micelle body in which paclitaxel is encapsulated in a block copolymer of polyethylene glycol and polyaspartic acid
- DHA fatty acid docosahexaenoic acid
- Texoplexin a prodrug in which polyglutamic acid is combined with paclitaxel
- a monoclonal antibody that targets tumor cells is paclitaxel.
- a nanoparticle preparation in which paclitaxel, which is one of the preferred preparation forms of paclitaxel of the present invention, is encapsulated with albumin can be produced, for example, according to the method described in JP-A-2003-300878.
- a commercially available product such as an albumin-bound paclitaxel suspension for injection sold under the trade name “Abraxane” can also be used.
- the blending ratio of paclitaxel in the antitumor agent of the present invention is not particularly limited as long as the antitumor effect is enhanced.
- the daily amount of paclitaxel may be about 0.01 to 100 mol, preferably about 0.1 to 30 mol, particularly preferably about 0.3 to 10 mol, per mol of tegafur.
- the antitumor agent of the present invention is a combination agent containing tegafur, gimeracil and oteracil potassium, a combination agent containing 1-OHP and paclitaxel so as to have the above mixing ratio (a preparation containing a plurality of active ingredients).
- the above active ingredient is a single agent (preparation containing a single active ingredient) or a compounding agent so that it can be used at the same time or at intervals, even if it is formulated into a single dosage form (single dosage form) As a plurality of dosage forms (multi-dose form).
- a preparation containing l-OHP and a preparation containing paclitaxel were prepared as single agents, respectively, and a combination preparation containing tegafur, gimeracil and oteracil potassium formulated separately was combined into a multi-drug form. Is preferably used.
- the tumor that can be treated with the antitumor agent of the present invention is not particularly limited.
- the dosage form of the preparation is not particularly limited and can be appropriately selected depending on the purpose of treatment. Specific examples include oral preparations (tablets, coated tablets, powders, granules, capsules, liquids, etc.), injections, suppositories, patches, ointments and the like.
- oral preparations tablets, coated tablets, powders, granules, capsules, liquids, etc.
- injections suppositories
- patches ointments and the like.
- the antitumor agent of the present invention is formulated into a plurality of dosage forms, the preparations may be in different dosage forms or in the same dosage form.
- tegafur, gimeracil and oteracil potassium are preferably used as an oral preparation
- a preparation containing 1-OHP and paclitaxel is preferably used as an injection.
- an antitumor agent containing three components of tegafur, gimeracil and oteracil potassium as active ingredients is used for the purpose of treating malignant tumors in mammals including humans. It can be appropriately selected depending on the situation. Specifically, oral preparations such as injections, suppositories, eye drops, ointments, aerosols, tablets, coated tablets, powders, granules, capsules, solutions, pills, suspensions, emulsions, etc. An agent can be exemplified, and an oral dosage form is preferable.
- the above-mentioned administration agent is produced by a formulation method generally known in this field.
- the dosage unit form used when a drug containing 1-OHP as an active ingredient is used for the purpose of treating malignant tumors of mammals including humans is not particularly limited, and can be appropriately selected according to the purpose of treatment.
- oral preparations such as injections, suppositories, eye drops, ointments, aerosols, tablets, coated tablets, powders, granules, capsules, solutions, pills, suspensions, emulsions, etc.
- An agent can be exemplified, and is preferably an injection dosage form, and an intravenous, intramuscular and subcutaneous route of administration is particularly preferred.
- the above-mentioned administration agent is produced by a formulation method generally known in this field.
- the dosage unit form used when a drug containing paclitaxel as an active ingredient is used for the purpose of treating malignant tumors in mammals including humans is not particularly limited, and can be appropriately selected depending on the purpose of treatment.
- oral preparations such as injections, suppositories, eye drops, ointments, aerosols, tablets, coated tablets, powders, granules, capsules, solutions, pills, suspensions, emulsions, etc.
- An agent can be exemplified, and is preferably an injection dosage form, and an intravenous, intramuscular and subcutaneous route of administration is particularly preferred.
- the above-mentioned administration agent is produced by a formulation method generally known in this field.
- the antitumor agent of the present invention may be individually manufactured, packaged and distributed for each of the above preparations as long as a combination drug containing tegafur, gimeracil and oteracil potassium, l-OHP and paclitaxel are administered in combination. . Further, all or a part of the above preparation may be produced, packaged and distributed as a single package (kit preparation) suitable for combined administration.
- each active ingredient in the present invention can be prepared by a generally known method using a pharmacologically acceptable carrier.
- pharmacologically acceptable carriers include various types commonly used for ordinary drugs, such as excipients, binders, disintegrants, lubricants, diluents, solubilizers, suspending agents, isotonic agents, pH. Examples include regulators, buffers, stabilizers, colorants, flavoring agents, and flavoring agents.
- excipients include lactose, sucrose, sodium chloride, glucose, maltose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silica
- examples include acids, methylcellulose, glycerin, sodium alginate, gum arabic, and mixtures thereof.
- the lubricant include purified talc, stearate, borax, polyethylene glycol, and a mixture thereof.
- binder examples include simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, carboxymethyl cellulose, shellac, methyl cellulose, ethyl cellulose, water, ethanol, potassium phosphate, and a mixture thereof.
- disintegrant examples include dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and mixtures thereof. Is mentioned.
- Examples of the diluent include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and mixtures thereof.
- Examples of the stabilizer include sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, and a mixture thereof.
- Examples of the isotonic agent include sodium chloride, boric acid, glucose, glycerin and a mixture thereof.
- Examples of the pH adjuster and buffer include sodium citrate, citric acid, sodium acetate, sodium phosphate, and mixtures thereof.
- Examples of soothing agents include procaine hydrochloride, lidocaine hydrochloride, and mixtures thereof.
- each active ingredient in the antitumor agent of the present invention is not particularly limited as long as it is an amount that achieves each compounding purpose.
- the dosage of tegafur is 20 to 500 mg / m 2 (per body surface area) / day, preferably 60 to 120 mg / m 2 / day.
- 58.8 to 117.6 mg / m 2 / day can be exemplified.
- Examples of the dose of 1-OHP include 40 to 300 mg / m 2 / day, preferably 80 to 150 mg / m 2 / day.
- Examples of the dose of paclitaxel include 10 to 1000 mg / m 2 / day, preferably 50 to 500 mg / m 2 / day.
- the antitumor agent of the present invention preferably contains a combination drug containing tegafur, gimeracil and oteracil potassium, l-OHP and paclitaxel so that the daily dose is the above dose.
- a compounding agent containing tegafur, gimeracil and oteracil potassium is 20 to 500 mg / m 2 , preferably 60 to 120 mg / m 2 in terms of tegafur as a daily dose, and 40 daily as 1-OHP. It is preferable to contain ⁇ 300 mg / m 2 , preferably 80 to 150 mg / m 2 , and paclitaxel as a daily dose of 10 to 1000 mg / m 2 , preferably 50 to 500 mg / m 2 .
- the administration schedule (administration order and administration interval) of each active ingredient in the present invention is not particularly limited as long as a synergistic effect is obtained.
- antitumor agent of the present invention when used as a kit, individual preparations may be administered simultaneously or at intervals.
- the above combination of tegafur, gimeracil and oteracil potassium, l-OHP-containing preparation and paclitaxel-containing preparation (A) an antitumor composition comprising a therapeutically effective amount of tegafur, an effective amount of gimeracil for enhancing antitumor effect, and an effective amount of oteracil potassium for suppressing side effects; From a combination of pharmaceutical compositions for treating tumors in mammals comprising (b) a composition containing a therapeutically effective amount of l-OHP, and (c) a composition containing a therapeutically effective amount of paclitaxel It can be set as a kit.
- each composition constituting the kit can be made into various known preparation forms, and each composition is generally stored in various commonly used containers according to the preparation form.
- a kit comprising a combination of pharmaceutical compositions for tumor treatment means a kit containing a pharmaceutical composition in any combination or a kit containing all active ingredients in one form.
- the kit includes, for example, at least three compositions comprising the above (a) to (c), and at least two containers for these compositions, wherein (a) and (c) are different.
- a kit for treating a tumor in a mammal that is housed in a separate container.
- the above compositions (a) to (c) are preferably in the form of preparations combined with a pharmaceutically acceptable carrier.
- it is sufficient that (a) and (c) are housed in separate containers, and (b) may be housed in a separate container from the two compositions, (a) or It may be mixed with (c) and accommodated in the same container.
- kit may include package inserts, labels, instructions for use, and the like.
- the package insert, label, instruction manual, etc. may describe, for example, administering at least three compositions comprising the above (a) to (c) in combination.
- Example 1 Combined effect of paclitaxel on antitumor effect of TS-1 + 1-OHP against human gastric cancer line SC-2
- HPMC hydroxypropylmethylcellulose
- L-OHP was dissolved in a 5% glucose solution for injection (Otsuka sugar solution, manufactured by Otsuka Pharmaceutical Factory) to prepare an l-OHP preparation.
- Paclitaxel was dissolved in an equal volume mixture of Cremophor (registered trademark) EL and ethanol and diluted with physiological saline immediately before administration to prepare a paclitaxel preparation (hereinafter also referred to as “TXL”).
- Docetaxel was added to the stock solution according to the package insert of the commercial preparation for administration, and diluted with physiological saline immediately before administration to prepare docetaxel preparation (hereinafter also referred to as “TXT”).
- TXT docetaxel preparation
- the TS-1 preparations were orally administered once a day for 14 consecutive days from the next day (day 1) after grouping, at the doses shown in Table 1 below (as tegafur amounts).
- the l-OHP preparation was administered at 5 mg / kg, the paclitaxel preparation at 10 mg / kg and 20 mg / kg, and the docetaxel preparation at 10 mg / kg, both of which were administered into the tail vein on the following day (Day 1) and Day 8. .
- the ratio of tumor volume at the time of grouping (day 0) and day 15 was defined as a relative tumor volume (RTV).
- the tumor growth inhibition rate (%) was calculated by the following formula 1 from the average value of the relative tumor volume of the drug administration group and the average value of the relative tumor volume of the cancer-bearing control group (no drug administration). [Formula 1] [(1- (Relative tumor volume in the dosing group) / (Relative tumor volume in the tumor-bearing control group)) ⁇ 100 (%)]
- HPMC hydroxypropylmethylcellulose
- L-OHP was dissolved in a 5% glucose solution for injection (Otsuka Sugar Solution, manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) to prepare an l-OHP preparation.
- a freeze-dried powder of human serum albumin-binding nanoparticle paclitaxel was suspended in physiological saline and used as a human serum albumin-binding nanoparticle paclitaxel formulation (hereinafter referred to as “APX formulation”).
- APX formulation human serum albumin-binding nanoparticle paclitaxel formulation
- the TS-1 preparations were orally administered once a day for 14 consecutive days from the next day (day 1) after grouping, at the doses shown in Table 1 below (as tegafur amounts).
- the l-OHP preparation was administered into the tail vein at 5 mg / kg on the next day (1st day) and 8th day after grouping.
- the APX preparations were administered via tail vein at 20 mg / kg or 40 mg / kg (as paclitaxel amount) on the next day (1st day) and 8th day after grouping.
- the ratio of tumor volume at the time of grouping (day 0) and day 15 was defined as a relative tumor volume (RTV).
- the tumor growth inhibition rate (%) was calculated by the following formula 3 from the average value of the relative tumor volume of the drug administration group and the average value of the relative tumor volume of the cancer-bearing control group (no drug administration). [Formula 3] [(1- (Relative tumor volume in the dosing group) / (Relative tumor volume in the tumor-bearing control group)) ⁇ 100 (%)]
- the presence / absence of the additional effect of the combined use was analyzed by the IUT method (Intersection-Union test) using the relative tumor volume on the 15th day.
- Example 3 Tumor growth inhibitory effect by combined use of TS-1 / 1-OHP / paclitaxel against human gastric cancer strain SC-2 A preparation for administration and preparation were administered in the same manner as in Example 2.
- the tumor diameter was measured 2 to 3 times a week including the grouping date for a total of 4 weeks including the observation period of 2 weeks after the end of drug administration, and the average value of the relative tumor volume in each group was 4.
- the time to reach (relative tumor volume 4 (days)) was calculated.
- a value obtained by subtracting the relative tumor volume 4 of the cancer-bearing control group from the relative tumor volume 4 of the drug-administered group was determined and used as the growth delay period (days).
- [Formula 5] [Relative tumor volume in dosing group 4—Relative tumor volume in cancer-bearing control group 4 (days)] The obtained results are shown in Table 3.
- the growth delay period is 2.2 days for the conventional TS-1 / 1-OHP combination therapy, and 10.8 days and 14.4 days for the APX preparations 20 mg / kg and 40 mg / kg. .
- the APX preparations 20 mg / kg and 40 mg / kg are used in combination with the TS-1 / 1-OHP combination therapy of the present invention, 17.0 days and 19.4 days are obtained.
- a delay effect was shown. This suggests that concomitant use of paclitaxel with TS-1 / 1-OHP combination therapy leads to excellent life extension in the treatment of tumor patients.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本出願は、2012年3月16日に出願された、日本国特許出願第2012-059987号明細書(その開示全体が参照により本明細書中に援用される)に基づく優先権を主張する。
(a)治療に有効な量のテガフール、抗腫瘍効果増強のために有効な量のギメラシル、及び副作用抑制のために有効な量のオテラシルカリウムを含有する抗腫瘍組成物、
(b)治療に有効な量のl-OHPを含有する組成物、並びに
(c)治療に有効な量のパクリタキセルを含有する組成物
からなる哺乳動物における腫瘍治療のための医薬組成物の組み合わせからなるキットとすることができる。該キットでは、これを構成する各組成物は公知の各種の製剤形態とすることができ、一般に各々の組成物は、その製剤形態に応じて、通常用いられる各種の容器に収納される。
[投与製剤の調製]
テガフール・ギメラシル・オテラシルカリウム配合剤(テガフール:ギメラシル:オテラシルカリウム(モル比)=1:0.4:1、TS-1)を0.5%ヒドロキシプロピルメチルセルロース(HPMC)水溶液に懸濁し、TS-1製剤を調製した。
[製剤の投与]
ヒト胃癌SC-2株の2mm角のフラグメントを雄性ヌードマウスBALB/c-nu/nuの背部皮下に移植した。腫瘍体積(=0.5×長径[mm]×短径[mm]×短径[mm])の平均値が約160mm3となった段階で、マウスを群分けした(1群7匹、0日目)。
[式1] 〔(1-(投薬群の相対腫瘍体積)/(担癌対照群の相対腫瘍体積))×100 (%)〕
[式2] 〔((15日目のマウス体重-0日目のマウス体重)/0日目のマウス体重)×100(%)〕
得られた結果を表1に示す。
[投与製剤の調製]
テガフール・ギメラシル・オテラシルカリウム配合剤(テガフール:ギメラシル:オテラシルカリウム(モル比)=1:0.4:1、TS-1)を0.5%ヒドロキシプロピルメチルセルロース(HPMC)水溶液に懸濁し、TS-1製剤を調製した。
[製剤の投与]
ヒト胃癌SC-2株の2mm角のフラグメントを雄性ヌードマウスBALB/c-nu/nuの背部皮下に移植した。腫瘍体積(=0.5×長径[mm]×短径[mm]×短径[mm])の平均値が約120mm3となった段階で、マウスを群分けした(1群6匹、0日目)。
[式3] 〔(1-(投薬群の相対腫瘍体積)/(担癌対照群の相対腫瘍体積))×100 (%)〕
[式4] 〔((15日目のマウス体重-0日目のマウス体重)/0日目のマウス体重)×100(%)〕
得られた結果を表2に示す。
実施例2と同様な方法で投与製剤の調製、製剤の投与を行った。
[式5] 〔投薬群の相対腫瘍体積4-担癌対照群の相対腫瘍体積4 (日)〕
得られた結果を表3に示す。
Claims (17)
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤、オキサリプラチン、並びにパクリタキセルを組み合わせてなる抗腫瘍剤。
- 前記配合剤が、テガフール、ギメラシル及びオテラシルカリウムを、テガフール:ギメラシル:オテラシルカリウム=1:0.4:1のモル比で含有するものである請求項1記載の抗腫瘍剤。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤、オキサリプラチンを含有する製剤、並びにパクリタキセルを含有する製剤とからなる製剤形態である請求項1~2のいずれか1項記載の抗腫瘍剤。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤が経口による投与経路により、オキサリプラチンを含有する製剤並びにパクリタキセルを含有する製剤がそれぞれ静脈内、筋肉内及び皮下からなる群から選ばれる投与経路により、投与されることを特徴とする請求項3に記載の抗腫瘍剤。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤、オキサリプラチンを含有する製剤、並びにパクリタキセルを含有する製剤が、同時に或いは間隔を空けて投与されることを特徴とする、請求項3~4のいずれか1項記載の抗腫瘍剤。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤を、1日量としてテガフール換算量で60~120mg/m2、オキサリプラチンを、1日量として80~150mg/m2、並びに、パクリタキセルを、1日量として50~500mg/m2、それぞれ含有する請求項1~5のいずれか1項記載の抗腫瘍剤。
- パクリタキセルの製剤形態が、パクリタキセルをアルブミンで封入したナノ粒子製剤であるである、請求項3~6のいずれか1項記載の抗腫瘍剤。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤、オキサリプラチンを含有する製剤、並びにパクリタキセルを含有する製剤とからなるキット。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤、オキサリプラチン、並びにパクリタキセルを併用投与することを特徴とする、腫瘍の治療方法。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤、オキサリプラチン、並びにパクリタキセルを併用した腫瘍治療のための、テガフール、ギメラシル、オテラシルカリウム、オキサリプラチン及びパクリタキセルの使用。
- テガフール、ギメラシル、及びオテラシルカリウムを含有する抗腫瘍組成物、オキサリプラチンを含有する抗腫瘍組成物、並びにパクリタキセルを含有する抗腫瘍組成物からなる腫瘍治療のための医薬組成物の組み合わせ。
- オキサリプラチン及びパクリタキセルと併用して腫瘍治療に用いるための、テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤。
- オキサリプラチン及びパクリタキセルと同時に或いは間隔を空けて投与し腫瘍患者を治療するための、テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤を含むキットであって、腫瘍患者を治療するために、前記配合剤と、オキサリプラチン及びパクリタキセルとを組み合わせて投与することが記載された添付文書、ラベル又は使用説明書を含むことを特徴とするキット。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤及びオキサリプラチンと併用して腫瘍治療に用いるための、パクリタキセル。
- テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤及びオキサリプラチンと同時に或いは間隔を空けて投与して腫瘍患者を治療するための、パクリタキセル。
- パクリタキセルを含むキットであって、腫瘍患者を治療するために、前記パクリタキセルと、テガフール、ギメラシル及びオテラシルカリウムを含有する配合剤並びにオキサリプラチンとを組み合わせて投与することが記載された添付文書、ラベル又は使用説明書を含むことを特徴とするキット。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20147028594A KR20140144213A (ko) | 2012-03-16 | 2013-03-15 | 3제를 조합한 신규 항종양제 |
RU2014141615A RU2014141615A (ru) | 2012-03-16 | 2013-03-15 | Новое противоопухолевое средство, включающее комбинацию трех агентов |
EP13760458.3A EP2826482A4 (en) | 2012-03-16 | 2013-03-15 | NOVEL ANTITUMOR AGENT COMPRISING AN ASSOCIATION OF THREE AGENTS |
AU2013233094A AU2013233094A1 (en) | 2012-03-16 | 2013-03-15 | Novel antitumor agent comprising combination of three agents |
US14/385,187 US20150110864A1 (en) | 2012-03-16 | 2013-03-15 | Novel antitumor agent comprising combination of three agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-059987 | 2012-03-16 | ||
JP2012059987 | 2012-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013137433A1 true WO2013137433A1 (ja) | 2013-09-19 |
Family
ID=49161329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/057403 WO2013137433A1 (ja) | 2012-03-16 | 2013-03-15 | 3剤を組み合わせた新規な抗腫瘍剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150110864A1 (ja) |
EP (1) | EP2826482A4 (ja) |
JP (1) | JPWO2013137433A1 (ja) |
KR (1) | KR20140144213A (ja) |
AU (1) | AU2013233094A1 (ja) |
RU (1) | RU2014141615A (ja) |
WO (1) | WO2013137433A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016008215A (ja) * | 2014-06-24 | 2016-01-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとs−1(もしくは5−fu)の使用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015208060A1 (de) * | 2015-02-12 | 2016-08-18 | Ifm Electronic Gmbh | Verfahren zum Betrieb eines Impulsgenerators für kapazitive Sensoren und Impulsgenerator |
KR102258514B1 (ko) * | 2019-09-23 | 2021-05-31 | 연세대학교 산학협력단 | 신규한 다층형 좌약 제제 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2614164B2 (ja) | 1991-05-27 | 1997-05-28 | 大鵬薬品工業株式会社 | 抗腫瘍効果増強のための及び腫瘍治療のための組成物 |
JP2003300878A (ja) | 2002-03-29 | 2003-10-21 | Acs Dobfar Spa | パクリタキセルおよびアルブミンのナノ粒子を作製する方法 |
WO2005120480A1 (ja) | 2004-06-09 | 2005-12-22 | Taiho Pharmaceutical Co., Ltd. | 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法 |
-
2013
- 2013-03-15 US US14/385,187 patent/US20150110864A1/en not_active Abandoned
- 2013-03-15 WO PCT/JP2013/057403 patent/WO2013137433A1/ja active Application Filing
- 2013-03-15 EP EP13760458.3A patent/EP2826482A4/en not_active Withdrawn
- 2013-03-15 AU AU2013233094A patent/AU2013233094A1/en not_active Abandoned
- 2013-03-15 RU RU2014141615A patent/RU2014141615A/ru not_active Application Discontinuation
- 2013-03-15 JP JP2014505020A patent/JPWO2013137433A1/ja active Pending
- 2013-03-15 KR KR20147028594A patent/KR20140144213A/ko not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2614164B2 (ja) | 1991-05-27 | 1997-05-28 | 大鵬薬品工業株式会社 | 抗腫瘍効果増強のための及び腫瘍治療のための組成物 |
JP2003300878A (ja) | 2002-03-29 | 2003-10-21 | Acs Dobfar Spa | パクリタキセルおよびアルブミンのナノ粒子を作製する方法 |
WO2005120480A1 (ja) | 2004-06-09 | 2005-12-22 | Taiho Pharmaceutical Co., Ltd. | 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法 |
Non-Patent Citations (10)
Title |
---|
CANCER, vol. 109, 2007, pages 33 - 40 |
HIROSHI NEMOTO ET AL.: "Shokaki (Shokudo - I - Daicho) Gan Kagaku Ryoho ni Taisuru Watashitachi no Torikumi", IYAKU NO MON, vol. 47, no. 3, 2007, pages 271 - 279, XP008174862 * |
HIROYA TAKIUCHI: "Shinki Saibo Dokusei Koganzai no Kiso to Rinsho", G. I. RESEARCH, vol. 14, no. 1, 2006, pages 11 - 19, XP008174990 * |
J. CLIN. ONCOL., vol. 27, no. 15S, 2009, pages 4553 |
NARIKAZU BOKU: "DPD Inhibitory Fluoropyrimidine (DIF) in Gastrointestinal Malignancies", BIOTHERAPY, vol. 17, no. 4, 2003, pages 361 - 367, XP008174795 * |
ONCOLOGY, vol. 74, no. 1-2, 2008, pages 37 - 41 |
SATOH, H. ET AL.: "S-1 for the treatment of gastrointestinal cancer", EXPERT OPINION ON PHARMACOTHERAPY, vol. 13, no. 13, September 2012 (2012-09-01), pages 1943 - 1959, XP008174798 * |
See also references of EP2826482A4 * |
YASUHIRO ODERA ET AL.: "Shokaki Gan Kagaku Ryoho no Key Drug", GASTROENTEROLOGICAL SURGERY NURSING, vol. 11, no. 9, 2006, pages 874 - 886, XP008174816 * |
YASUHIRO TERASAKI ET AL.: "P3-089 Toin ni Okeru Genpatsu Fumei Gan 10 Rei no Kento", THE 9TH ANNUAL MEETING OF JAPANESE SOCIETY OF MEDICAL ONCOLOGY PROGRAM - SHOROKUSHU, 2011, pages 474, XP008174988 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016008215A (ja) * | 2014-06-24 | 2016-01-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとs−1(もしくは5−fu)の使用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2013137433A1 (ja) | 2015-08-03 |
RU2014141615A (ru) | 2016-05-10 |
AU2013233094A1 (en) | 2014-10-23 |
US20150110864A1 (en) | 2015-04-23 |
EP2826482A1 (en) | 2015-01-21 |
KR20140144213A (ko) | 2014-12-18 |
EP2826482A4 (en) | 2015-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI594986B (zh) | Antineoplastic agent effect enhancer | |
ES2848706T3 (es) | Terapia de combinación contra el cáncer usando un compuesto azabicíclico | |
JPWO2014157444A1 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
JP2009536956A (ja) | 抗癌治療法 | |
JP2021523189A (ja) | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組成物およびその使用方法 | |
WO2010086964A1 (ja) | がん治療のための併用療法 | |
JP2021523169A (ja) | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
WO2013137433A1 (ja) | 3剤を組み合わせた新規な抗腫瘍剤 | |
JP6973456B2 (ja) | 癌化学療法時の副作用軽減剤 | |
JPWO2004081012A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
ZA200700134B (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
ES2747073T3 (es) | Combinación de RO5503781, capecitabina y oxaliplatino para el tratamiento del cáncer | |
JP5409613B2 (ja) | 抗腫瘍剤、キット及び癌治療方法 | |
JP6488280B2 (ja) | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
WO2010131460A1 (ja) | テガフール・ギメラシル・オテラシルカリウム配合剤及びオキサリプラチンを含有する抗腫瘍剤 | |
JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
WO2011152516A1 (ja) | キナーゼ阻害剤を組み合わせた抗腫瘍剤 | |
CN106176757B (zh) | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 | |
WO2011152515A1 (ja) | インドール化合物を含有する抗腫瘍剤 | |
JP2015199676A (ja) | レゴラフェニブを含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
WO2009119092A1 (ja) | シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤 | |
JP2015199677A (ja) | ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13760458 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014505020 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147028594 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013760458 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014141615 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013233094 Country of ref document: AU Date of ref document: 20130315 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14385187 Country of ref document: US |